Malondialdehyde (MDA), an oxidation product of polyunsaturated fatty acids, is used as an in vivo marker to assess lipid peroxidation in diseases such as atherosclerosis and diabetes (1) (2) (3) (4) . In biological matrixes, MDA is measured after derivatization with thiobarbituric acid (TBA) (5 ) . Because TBA reacts with many other aldehydes (6 ) , results are expressed as TBA-reactive substances (TBARS). Several problems are associated with TBARS analysis, in particular, low reproducibility and a lack of specificity that leads to overestimations. To overcome these difficulties, more specific methods have been proposed that require sample pretreatment to precipitate proteins and extract MDA-reactant adducts (6 -9 ) . This additional step is time-consuming and adversely affects precision. The aim of the present study was to develop a rapid and sensitive method to measure MDA in plasma, avoiding sample pretreatment.
Tetraethoxypropane (TEP), TBA, and bilirubin were obtained from Fluka. Fatty acid-free bovine serum albumin (BSA), Total Protein Reagent, and Protein Standard were from Sigma, and 2,2Ј-azobis(2-amidinopropane) (ABAP) was from Wako.
We prepared an aqueous stock solution of 1 mmol/L TEP. A 10 mol/L MDA solution was obtained by diluting TEP in 0.1 mol/L HCl. A 0.025 mol/L TBA solution was prepared daily by dissolving TBA in water. BSA solutions were prepared in 0.1 mol/L HCl. To remove protein-bound MDA, BSA solutions were heated at 80°C for 1 h and dialyzed for 3 days against 0.1 mol/L HCl in a 3500-Da cutoff dialysis membrane (Spectrapore; Spectrum Medical Industries). The actual protein concentration was verified using the Total Protein Reagent Kit. A 50 mmol/L ABAP solution was prepared in water.
Six MDA solutions ranging from 0.05 to 0.5 mol/L were prepared by diluting the 10 mol/L stock solution with 0.1 mol/L HCl. Triplicate solutions were used to obtain a dose-response curve. Calibration curves in plasma were obtained by adding MDA (0.2-0.6 mol/L) in duplicate to six different plasma samples.
The MDA-TBA adduct (TMT) was synthesized according to Guzmán-Chozas et al. (10 ) . To investigate the effect of BSA on TMT fluorescence, we transferred 0.2, 0.4, and 0.6 mol/L acidic TMT solutions (pH 2) to a magnetically stirred cuvette in a FL 55 Perkin-Elmer spectrofluorometer at 30°C and recorded the fluorescence emission spectra at 549 nm (excitation at 520 nm). BSA (80 g/L) was added to produce a concentration of 10 g/L, and the spectra were recorded again. To study the effect of BSA concentration on TMT fluorescence, we assayed the same TMT solutions in the presence of 1.3-25 g/L BSA.
For circular dichroism (CD) spectroscopy, we used a J-715 spectropolarimeter (Jasco) operating at 37°C; spectra were recorded at 0.8 g/L protein with a 10-mm cell path length. Molar ellipticity was calculated according to:
where ⌰ is the measured ellipticity (in millidegrees) at the given wavelength , MRW is the mean residue molecular weight (114 for BSA), l is the cell path in mm, and c is the protein concentration in g/L. Measurements were carried out in the 300 -600 nm region. Transition to an acid-denatured state was achieved by exposing protein to solutions containing 10 mmol/L potassium phosphate and HCl to reach pH 2.
For the assay, 200 L of MDA or the EDTA-plasma samples was added to 700 L of 0.1 mol/L HCl (pH 2). After 20 min at room temperature, 900 L of 0.025 mol/L TBA was added, and the solution was maintained at 37°C for 65 min. A 1.6-mL aliquot was transferred to a cuvette (kept at 37°C); 400 L of 120 g/L BSA was then added and the emission recorded (549 nm).
Precision was assessed by analyzing pooled plasma and two calibrator solutions for within-and between-run SD. The detection and quantification limits were calculated according to EURACHEM guidelines (11 ) . MDA recovery experiments were performed by incubating plasma with different added concentrations of MDA (final concentrations, 0.2, 0.4, and 0.6 mol/L). To ensure that bilirubin did not interfere with the fluorometric detection of TMT, the pigment (12 mol/L) was added to a plasma sample.
We used the method to measure lipid peroxidation in plasma oxidized in vitro with ABAP. Aliquots of pooled EDTA plasma were added to four tubes. ABAP was then added to three of the tubes to give final concentrations of 4.9, 9.5, and 14 mol/L. The tubes were incubated at 38°C for 4 h, and MDA was determined. The experiment was repeated three times. Finally, the method was used to measure MDA in the plasma of 12 healthy human volunteers.
The presence of protein led to enhancement of the fluorescence of the TMT adduct, as demonstrated by the linear increase in fluorescence intensity at 549 nm ( Table  1) . The fluorescence reached a plateau at a final protein concentration of 20 g/L. On the basis of these results, BSA was added to plasma samples to reach a concentration of 24 g/L before MDA detection.
CD has been often used to study the binding of small molecules to proteins (12 ) . Optically active small molecules show a change in CD on binding to a macromolecule, either because of electronic interactions with the binding site or conformational changes. These changes can be easily detected because most biopolymers have no CD in the visible light region. We used CD to investigate the binding of albumin to TMT (Fig. 1) . The change in spectra suggests that the fluorescence enhancement of the adduct is attributable to the binding of TMT to BSA.
Below pH 3, human serum albumin acquires a molten globule-like state (13 ) , characterized by a substantial amount of secondary structure and a largely disordered tertiary structure (14 ) . It is reasonable to assume that under our analytical conditions BSA is in the molten globule-like state, with exposed hydrophobic surfaces facilitating binding to TMT. To establish whether the same enhancing effect of BSA could be observed in the presence of plasma, 200 L of human plasma containing 80 g/L total protein was added to 0.4 mol/L TMT. An increase in fluorescence intensity was observed similar to that obtained with BSA [215.9 (1.9) vs 217.6 (1.4); n ϭ 3].
On the basis of the enhancing effect of albumin on TMT fluorescence, we have developed a rapid and sensitive method to assess MDA in human plasma without sample pretreatment. The optimal reaction rate between MDA and TBA in the presence of albumin was obtained at 40°C. Nevertheless, we carried out the assay at 37°C, slightly sacrificing sensitivity but maintaining plasma in a physiologic condition. A HCl concentration of 0.1 mol/L was adequate to catalyze the reaction between MDA and TBA, as reported previously (6 ), while maintaining the albumin enhancement effect.
The dose-response curve for aqueous solutions has been calculated between 0.05 and 0.5 mol/L MDA (y ϭ 138.79 Ϯ 3.21x, where y is the fluorescence intensity in arbitrary fluorescence units and x is MDA concentration in mol/L; R 2 ϭ 0.999). In the case of dose-response curves in plasma with added MDA, no matrix effect was observed [mean (SD) sensitivity from six different calibration curves, 140.68 (6.19)]. The detection and quantification limits were 0.015 and 0.025 mol/L, respectively. Within-(n ϭ 10) and between-run (n ϭ 10) relative SDs were 2% and 3.8%, respectively, for aqueous calibrator solutions and 3.7% and 8.4% for plasma. The mean recovery, calculated on the basis of 20 experiments at three different MDA concentrations, was 97.3% Ϯ 4.3%.
The effects of contaminants under conditions similar to those used in the current study have been described (6 ) . The reaction rate for TBA and common aldehydes at 65°C is markedly lower than the reaction rate for TBA and MDA, allowing analysis at a contaminant:analyte ratio up to 100:1 by weight (6 ) . Because plasma is used in our method, hemoglobin, bilirubin, or high concentrations of triglycerides could affect the results. Bilirubin showed no effect at physiologic concentrations. Regarding hemoglobin, the use of hemolyzed samples should be always avoided when oxidative status is measured because the cellular enzymes released may oxidize plasma components, inducing artificial peroxidation products. Triglyc- (5, 15 ) .
In conclusion, the proposed method is sensitive, rapid, easy to perform, and able to detect plasma MDA without overestimation as a result of sample handling, other interfering species, and matrix artificial oxidation. The HLA genes of the MHC on chromosome 6p manifest extensive allelic polymorphism and haplotype diversity comprising sequence-related genes and pseudogenes. Class II HLA DR molecules consist of noncovalent heteroduplexes derived from paired genes; a variable ␤-chain with a constant ␣-chain. Currently, more than 300 different alleles are recognized for the DRB1* locus (1 ). Exon 2 of this ␤-chain gene codes for many of the residues impinging on the peptide binding groove and has known nucleotide variants at more than one-third of 270 base positions. Except in rare homozygous individuals, genotyping of DRB1* produces frequent ambiguity because of shared sequence motifs among alleles and cis-trans uncertainty between polymorphisms.
For histocompatibility typing, DRB1* alleles are traditionally partitioned into groups that reflect serologic lineages. High-resolution genotyping often requires haplotype isolation using group-specific PCR (2, 3 ) or other methods (4, 5 ) to exclude some alleles and reduce complexity. Primer sites for group-specific amplification have traditionally involved the hypervariable region at the 5Ј end of exon 2. Blasczyk et al. (6 ) and Bergstrom et al. (7 ) have shown that sequence diversity within introns adjacent to exon 2 is also group-specific and can be used to separate alleles for unequivocal typing (8 ) . Priming from intron sites increases the available region for primer design and expands the number of DRB group and subgroup sets. In addition, intron-primed amplicons include exon 2 in its entirety, defining polymorphisms obscured by, or external to, exon primers.
We assessed a DRB1* typing strategy based on grouplevel resolution by sequence-specific oligonucleotide (SSO) hybridization, followed by sequencing of intronprimed amplicons, a combination that provides rapid identification of potential DRB1* alleles and subsequent separation of haplotypes for definitive typing. Sequencing results using intron primers were evaluated for resolution of ambiguities and genotyping accuracy.
DNA was extracted from whole blood samples submitted for routine typing or from proficiency surveys. Initial DRB1* typing was performed using a commercial SSO assay based on multiplexed oligonucleotide probes attached to fluorescent microspheres (One Lambda). Intron oligonucleotides as described by Kotsch et al. (8 ) were synthesized on a Perseptive Biosystems 8900 Synthesizer (ABI) and purified by reversed-phase HPLC (BioCad Sprint-ABI). Sense primers RB1 and RB6 (for DR 1 and DR 4 groups, respectively) were replaced with the alternative primers RB1a (5Ј-gga agt gtt cac agg gtg aag-3Ј) and RB6a (5Ј-ggc tgc gtg ttg tcg gg-3Ј). , and 20 pmol each of the forward and reverse primers. PCR conditions were the same for all primer pairs and consisted of 10 min of denaturation at 94°C; 10 two-temperature cycles between 94°C (30 s) and 65°C (50 s); and 20 three-temperature cycles of 94°C (30 s), 62°C (50 s), and 72°C (30 s). A 3-mL aliquot was electrophoresed on a 2% agarose gel to confirm the appropriate size band and estimate the concentration by comparison with a molecular mass ruler (Bio-Rad). After PCR, each reaction was digested (15 min at 37°C) with shrimp alkaline phosphatase (10 U; USB) and exonuclease I (50 U; USB) to remove residual nucleotides and primers. After digestion the reactions were incubated for 15 min at 80°C to denature the enzymes. Aliquots of the amplified DNA (30 -50 ng) were sequenced in both directions with ABI BigDye terminator mixture (10 L/reaction) and 3.2 pmol of forward or reverse sequencing primer. Four different forward primers were used: three as described previously (8 ) and one additional primer [2a (7); 5Ј-aga ccg ccc ctg tga cc-3Ј] for DR7 forward sequencing. This primer differs from Seq 2 primer (8 ) by one nucleotide substitution at the third position (A instead of G) and produces a stronger sequencing signal for DR7 alleles. The reverse primers were the same as the reverse PCR primers except that RB28 replaced RB39 in the sequencing reactions. Cycle sequencing was performed for 25 three-temperature cycles of 96°C (10 s), 50°C (5 s), and 60°C (4 min). The extension products were precipitated by centrifugation in isopropanol (600 mL/L) and run on an ABI Prism 377 automated sequencer with ABI Prism Sequence Analysis software. Sequence Navigator and Factura-HLA were used for editing and allele assignments.
More than 1300 samples were typed for DRB1* by SSO analysis, which completely resolved 13% of alleles to a single genotype. Assignments for the remaining alleles were ambiguous, with probe hybridization patterns matching multiple allele combinations; however, most samples were equivocal between only two DR groups. Failure to differentiate silent or intron polymorphisms was not considered an ambiguity for this assessment.
We reamplified 172 of the samples, using group-specific intron primers selected according to the SSO results. Fifty percent of sequenced alleles were from DR groups 1-4 and 25% were from groups 11 and/or 13. The remaining alleles were distributed among the other DR groups (Table 1 ). Sequencing produced allele-level resolution in 96% of samples. For 12% of samples, both alleles were assigned to the same DRB1* group, precluding separation with intron primers, but 7% of these were homozygous at DRB1* (exon 2), as confirmed by sequencing, and only seven samples (4%) remained ambiguous. Six of these involved codon 86 Gly/Val dimorphisms, for which specific exon primers were used for subsequent haplotyping (9 ). Sequencing of DRB1* genes with intron primers enabled separation of 14 different allele groups or intragroup subsets and, with codon 86 primers, completely resolved 99% of samples. Twenty-five percent of the samples were obtained from proficiency surveys and were in complete agreement with the consensus genotype compiled from participating laboratories.
DNA methods for HLA-DRB typing provide the highest resolution and most complete information of current typing techniques. DRB1* exon 2 genotyping is essential for bone marrow transplantation from unrelated donors and is being performed with increasing frequency for routine histocompatibility testing. The large number of closely related DRB alleles leads to frequent ambiguities that are resolved only by analyzing haplotypes separately.
Our typing strategy used an initial, intermediateresolution SSO to provide DRB1* group identity for subsequent sequencing, as opposed to first amplifying with all DR group primers and sequencing positive reactions (3 ) . This approach limits the number of secondary PCR reactions required, and only those samples requiring further, allele-level resolution are reamplified.
We have confirmed the use of intron primers for group-specific PCR and DNA sequencing as originally reported by Kotsch et al. (8 ) to resolve most DRB1* alleles and provide the complete exon 2 sequence. The specificity within intron sequence also extends to DRB3*, -4*, and -5* genes (6, 8 ) , which are coexpressed with certain DRB1* alleles. As a result, confusion resulting from amplification of these or from nonexpressed pseudogenes is avoided. Because sequence data for DRB introns are limited, the possibility of failed amplification because of primer mismatch adds a degree of uncertainty that both DRB1* alleles have been amplified. Previous SSO with generic DRB primers provides some assurance in this regard, whereas positive reactions from intron priming serve to confirm SSO results.
SSO can be performed after allele separation as well, but sequences not covered by oligonucleotide probes remain undefined, and assumptions are made regarding common probe combinations rather than unequivocal linkage. The sequencing of the complete DRB exon 2 and a partial intron sequence could serve to establish the frequency and locations of polymorphisms in this area and validate intron-primed amplicons as suitable templates for HLA typing.
